Sorafenib (SRF), a multikinase inhibitor drug used to manage advanced liver cancer, was also found to be effective against arthritis in an animal model, as it reduces the angiogenesis required for proliferation of inflammatory cells and reduces tissue vascular endothelial growth factor (VEGF) levels [8,9]. The gene discussed is VEGFA; the disease is arthritic joint disease.